At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
Ipilimumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-Related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies
In Brief
A Phase 2 clinical trial evaluating Ipilimumab and Laboratory Biomarker Analysis for Cervical Adenocarcinoma and 5 related conditions. Completed, enrolled 42 participants across 13 sites in 2 countries.
Detailed Summary
This phase II trial studies how well ipilimumab works in treating patients with human papilloma virus (HPV)-related cervical cancer that has come back or that has spread to other areas of the body. Monoclonal antibodies, such as ipilimumab, can find tumor cells and help kill them or carry tumor-killing substances to them.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Human Papillomavirus Infection, Recurrent Cervical Carcinoma, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVB Cervical Cancer AJCC v6 and v7
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 2012
Enrollment StartDec 2012
Primary CompletionMar 2021
Study CompletionNov 2021
TodayJul 2026
First PostedSep 26, 2012
Enrollment StartDec 3, 2012
Primary CompletionMar 18, 2021
Study CompletionNov 24, 2021
TodayJul 2, 2026
Enrollment to primary: 8.3 yearsPosted 13.8 years ago
Interventions
Ipilimumabbiological
Given IV
Laboratory Biomarker Analysisother
Correlative studies